The Mason, Ohio-based company posted losses of $338,000, or 1¢ per share, on sales of $51.8 million for the three months ended June 30, seeing losses shrink 95.1% while sales grew 14.5% compared with the same period last year.
Adjusted to exclude one-time items, losses per share were 19¢, ahead of the 23¢ loss-per-share consensus on The Street, where analysts were looking for sales of $49.9 million, which the company also topped
“Our second quarter results reflect strong revenue growth, solid operational performance and continued execution on our strategic priorities. We are pleased to be reporting positive adjusted EBITDA for the second quarter as well as raising our revenue expectations for the year,” prez & CEO Mike Carrel said in a press release.
AtriCure raised its sales guidance for the full year, expecting to post $193 million and $197 million.
Shares in AtriCure traded up 2.3% today, closing at $29.30.
In June, AtriCure said that it inked a multi-year partnership deal with China’s Baheal Pharmaceutical Group to distribute AtriCure’s surgical ablation devices.